Envonalkib

依奉阿克

Report date: 2026/03/04 20:01:44
NME

Base Information

Drug NameEnvonalkib
Drug Alias Name枸橼酸依奉阿克Envonalkib Citrate安洛晴TQ-B3139CT-1139 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAnaplastic lymphoma kinase inhibitorsHepatocyte growth factor receptor inhibitorsProto-oncogene tyrosine-protein kinase ROS inhibitors
TargetsAnaplastic lymphoma kinaseHepatocyte growth factor receptorProto-oncogene tyrosine-protein kinase ROS
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungNeoplasms
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryMainland China
Original Approved Date2024/06/11
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co LtdBeijing Centaurus Biopharma Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical GroupJiangsu Chia Tai-Tianqing Pharmaceutical Co LtdBeijing Centaurus Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A